Literature DB >> 32895630

Status epilepticus as a first presentation of COVID-19 infection in a 3 years old boy; Case report and review the literature.

Amir Saeed1, Eslam Shorafa1.   

Abstract

It was December 2019 that china reported series of patients with respiratory symptoms, a disease that later named COVID-19; and from there spread to other countries around the world; and in February 2020, the world health organization declared COVID-19 as a pandemic. From the beginning, it was assumed that COVID-19 occurrence in pediatric patients is less and has less severity but nowadays; there are a reports that shows severe cases with multiple organ involvement. The most manifestation symptom is fever but convulsion is rare as the first manifestation symptom. Here we describe a 3 years old; previously healthy boy that presented with repeated fever induced seizure and status epilepticus and positive RT-PCR for COVID-19 that in the first day; brain CT scan revealed brain edema and 5 days later, there was intracerebral hemorrhage in brain MRI.
© 2020 The Author(s).

Entities:  

Keywords:  COVID-19; ER, emergency room; GCS, Glasgow Coma Scale; MIS-C, multisystem inflammatory syndrome in children with COVID-19; PICU, pediatric intensive care unit; Pediatric; RT-PCR, reverse transcriptase polymerase chain reaction; Status epileticus; febrile seizure

Year:  2020        PMID: 32895630      PMCID: PMC7468313          DOI: 10.1016/j.idcr.2020.e00942

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

It was December 2019 that in Wuhan, China series of patients presented with respiratory symptoms [1], a disease that its cause, the novel coronavirus (SARS-COV-2), was identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and named COVID-19 and from China rapidly spread to other countries all around the world so that in February 2020 the world health organization declared it as a pandemic [[2], [3], [4]]. The rate of infection with covid-19 in children is low and the first pediatric case reported on January 20, 2020 was a 10 years old boy in Wuhan [4] and in the early phase of pandemic; those whom infected had relatively milder clinical symptoms compared with infected adults [5]; but as the time passed and the number of infected pediatric patients increased, there were several reports of multiple organ involvement in pediatric COVID-19 patients and according to the last reports [[6], [7], [8], [9]];WHO developed a new definition :” multisystem inflammatory syndrome in children with COVID-19 (MIS-C)” [10]. MIS-C definition criteria are: Children and adolescents 0–19 years of age with fever > 3 days, and two of the following: Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet). Hypotension or shock. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiography findings or elevated Troponin/NT-proBNP) Evidence of coagulopathy (by PT, PTT, and elevated d-Dimers). Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain). And; elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin. And; No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes. And; evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19 [10]. In this case report; we describe a 3 years old with MIS-C that his first presentation was: repeated seizures induced by fever (status epilepticus).

Case presentation

A 3 years old boy that was previously healthy, taken to emergency room (ER)of Namazi Hospital due to abnormal movement;(Namazi Hospital ;the largest hospital in south of Iran with 750 beds is located in Shiraz city that is the main tertiary referral center in south of Iran which has 18 bed general pediatric intensive care unit (PICU) and 9 bed surgery PICU).He was well up to 12 h prior to admission that presented with high grade fever (39.5 °C) so visited by a pediatrician that found no abnormal sign and just acetaminophen was prescribed for fever relief, but fever didn’t subside. He presented with oral foamy discharge and jerky movement of hands and feet about 30 min before admission in the hospital (he had history of contact in a ceremony, a day before, but no one that were there, had fever nor contact to suspected patients). On arrival to ER, his initial vital signs were: Glasgow coma score(GCS) :10/15 Heart rate(HR):160, respiratory rate(RR):45, blood pressure:110/78. In ER; the patient had two episodes of tonic colonic convulsions that lasted one minute with about 5 min interval that stopped with parenteral midazolam and due to repeated convulsions so phenobarbital started and transferred to PICU. In PICU, his GCS was 10/15 and had another tonic-clonic seizure so phenobarbital (5 mg/kg) in addition to levetiracetam 30 mg/kg was given; but convulsions didn’t stop so intubated and phenobarbital 1 mg/kg/hour and midazolam 1 mg/kg/hour intravenous infusion started and neuroprotection strategies were employed for him. In his initial laboratory data (listed in Table 1), WBC:6800 with 70 % neutrophil and 23 % lymphocyte, CRP: 105 were detected. Meropenem, vancomycin and acyclovir started for him and also reverse transcriptase–polymerase chain-reaction (RT-PCR) assay for COVID-19 with nasopharyngeal swan taken.
Table 1

Initial laboratory results.

Test (reference value) normal rangeResults
Ferritin (ng/ml) M*: 22.81–275 F*: 4.63–204212
COVID Real-time PCRPositive
White blood cells (count/ml)3600
Lymphocyte (count/ml)390
Procalcitonin ≤0.34.3
C- reactive protein (mg/L) <6105
Creatine phosphokinase (U/L) M: <171 F:<145195
Lactate dehydrogenase (U/L) <480900
Troponin (ng/ml) <1979
D-Dimer (ng/ml) <5003155
Calcium (mg/dl) 8.5–10.59.3
Magnesium (mg/dl) 1.6–2.61.6
Aspartate transaminase (U/L) M: <37 F: <3144
Alanine aminotransferase (U/L) M: <41 F: <3121
Albumin (g/dl) 3.5–54.3
Blood urea nitrogen (mg/dl) 8–2010
Creatinine (mg/dl) M: 0.8–1.3 F: 0.6–1.20.4
Prothrombin time/INR17.9/1.33
Partial thromboplastin (sec.)28.7
Blood cultureNegative
Erythrocyte sedimentation rate (mm/hr)45
Fibrinogen (200–400)366
Potassium (mEq/L) 3.5–5.54.1
Sodium (mEq/L) 135–145143
Typical Chest CT findingPatchy infiltration

*M: male, F: female.

Initial laboratory results. *M: male, F: female. In a brain CT scan in day 1; it showed a severe brain edema (Fig. 1) and chest CT scan was suspicious to COVID-19 (Fig. 2). A 24 h later; lumbar puncture (LP) was done that revealed: no cell, protein: 14 and sugar was 125 and cerebrospinal fluid (CSF) pressure was 33 cm of water(cmH2O).
Fig. 1

Brain CT on day of admission in PICU.

Fig. 2

Chest CT on day of admission in PICU, in favor of COVID-19.

Brain CT on day of admission in PICU. Chest CT on day of admission in PICU, in favor of COVID-19. The patient also fulfilled the criteria of “multi-system inflammatory syndrome associated with COVID-19(his initial RT-PCR was negative but the other one that sent 3 days later was positive). In day two, the patient became hypotensive so inotrope started but echocardiography was normal. In the following 2 days, inotrope increased to maintain normal mean arterial pressure and still the patient was febrile so intravenous globulin (IVIG) was given. (hydrocortisone, ascorbic acid and thiamine(HAT) had been started before) After IVIG infusion; we could decrease inotrope but still he had intermittent fever so brain MRI was done that revealed intracerebral hemorrhage in the right occipital lobe (Fig. 3).
Fig. 3

Brain MRI ;ICH in right occipital lobe.

Brain MRI ;ICH in right occipital lobe. In the 8th day, the patient extubated from ventilator and tolerated; his GCS was 15/15 with normal neurologic exam. On the 14th day, the patient discharged home with good condition.

Discussion

In the beginning; the rate of infected pediatric patients were less so it was believed that they are less susceptible and the most common symptoms in severe pediatric patients were; tachypnea, fever, cough, nausea/vomiting and diarrhea, fatigue/myalgia and headache [11]; but as the disease spread to other countries, there were reports that the first presentation were liver failure [9] or with the presentation of Kawasaki like disease with cardiac involvement [[6], [7], [8]], so we expect to see organ involvement in patients with COVID-19 even without respiratory symptoms. Before 2019, we had two outbreaks of coronaviruses: the severe acute respiratory syndrome (SARS) in 2002 and the Middle East respiratory syndrome (MERS) in 2012; that in both of them neurological manifestations in patients with respiratory tract infections with neuroinvasion had been described before [12]. Neurological problems found in the patients with coronavirus infection were: febrile seizures, convulsions, change in mental status, encephalomyelitis and encephalitis [12]. In SARS, the first cases with neurological manifestations presented with seizure [13,14]. In MERS, the most neurological presentations were seizure and encephalopathy [15] but intracerebral hemorrhage also have been reported [16]. In a retrospective study that Mao L et al. did in China; it showed: Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5.7 %), impaired consciousness (14.8 %), and skeletal muscle injury (19.3 %) but in their study mean age was 52.7 years [17]. In a multicenter retrospective study in 49 hospitals in Hubei, China by Lu L. et al. neither acute symptomatic seizures nor status epilepticus was observed [18]. Vollono C. et al. describe a 78 years old woman infected with COVID-19 whose primary presentation was a focal status epilepticus [19]. A 32 years old woman with fever and dry cough that developed with generalized tonic-clonic seizure reported by Karimi N. et al. that was positive for COVID-19 and her brain MRI was normal and CSF tested was negative for COVID [20]. Moriguchi J. et al. reported a 24 years old man with SARS-CoV-2 meningitis and convulsion that the specific SARS-CoV-2 RNA was not detected in the nasopharyngeal swab but was detected in a CSF [21]. In Iran; Sharifi-Razavi et al. described a 79 years old man with history of 3 days fever and acute loss of consciousness that had a massive intracerebral hemorrhage (ICH) in the right hemisphere, accompanied by intraventricular and subarachnoid hemorrhage and later, RT-PCR of oropharyngeal swab became positive [22]. Toscano G. et al. reported 5 adult patients developed Guillain–Barré syndrome 5–10 days after the onset of COVID-19 with an initial presentation of lower limb weakness, parasthesia and ataxia that their CSF’s RT-PCR were negative [23]. Shenker J. et al. reported a 12 years old boy with MIS-C presented with status epilepticus. Brain imaging, CSF cell count and PCR of CSF for COVID-19 were normal [24]. Coronaviruses has capability the neuroinvasion [12] and the presence of ACE2 receptors in the nervous system and in skeletal muscle are the suggesting a mechanism for SARS-CoV-2-related neuromuscular injury [25,26]. In kawasaki disease; altered mental status, seizures, and hemiplegia had been reported that was thought to be due to vasculitis [27]. Apart from ACE2, COVID-19-associated nervous system damage may also be caused by septic shock, hypoxic injury, fever (in children), metabolic derangements and immune responses. In our patient; RT-PCR of CSF was negative so one possibility of the repeated convulsions was autoimmune reaction and another was fever although direct invasion of virus cannot be excluded even with negative PCR but ICH that had been reported before [22], that could be co-incidence and related to his old age, but in our patient might be due to direct invasion of CNS by COVID-19. The above data indicate that SARS-CoV-2 may infect the nervous system and skeletal muscle as well as the respiratory tract especially in severe cases that have MIS-C; thus, clinicians should consider COVID-19 as a differential diagnosis for patients with neurological manifestations. In pediatric cases, it is important to emphasize that COVID19 could be another risk factor for febrile seizures (taking into account that other types of coronaviruses could also be involved) although it is known that influenza virus and enterovirus are the most frequently associated to this condition [28,29]. And even in the absence or respiratory symptoms, occurrence of neurologic symptoms might be the first presentation of COVID-19 and MIS-C and should be assessed for, especially in the critically ill pediatric patients.

Funding/Support

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors

Ethics approval and consent to participate

This study was approved by the ethics committee of Shiraz University of Medical sciences. Written informed consent was obtained from the parents and sent to the ethics committee.

Authors' contributions

Dr. Saeed planned the study and wrote the manuscript. Dr. Shorafa gathered patients' data and submitted the manuscript. Drs Saeed and Shorafa edited the manuscript. Both authors discussed the results and contributed to the final manuscript. The first presentation of COVID-19 in pediatric patient could be apart from respiratory complaint and pediatrician should be aware of nervous system complications of it.

Declaration of Competing Interest

The authors report no declarations of interest.
  10 in total

1.  Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study).

Authors:  Kursat Bora Carman; Mustafa Calik; Yasemin Karal; Sedat Isikay; Ozan Kocak; Aysima Ozcelik; Ahmet Sami Yazar; Cagatay Nuhoglu; Cigdem Sag; Omer Kilic; Meltem Dinleyici; Sibel Lacinel Gurlevik; Sevgi Yimenicioglu; Arzu Ekici; Peren Perk; Ayse Tosun; Ilhan Isik; Coskun Yarar; Didem Arslantas; Ener Cagri Dinleyici
Journal:  Hum Vaccin Immunother       Date:  2018-10-05       Impact factor: 3.452

Review 2.  Neurologic Alterations Due to Respiratory Virus Infections.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Mariana Ríos; Alexis M Kalergis
Journal:  Front Cell Neurosci       Date:  2018-10-26       Impact factor: 5.505

3.  Focal status epilepticus as unique clinical feature of COVID-19: A case report.

Authors:  Catello Vollono; Eleonora Rollo; Marina Romozzi; Giovanni Frisullo; Serenella Servidei; Alberto Borghetti; Paolo Calabresi
Journal:  Seizure       Date:  2020-04-21       Impact factor: 3.184

4.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome.

Authors:  Emily C W Hung; Stephen S C Chim; Paul K S Chan; Yu K Tong; Enders K O Ng; Rossa W K Chiu; Chi-Bon Leung; Joseph J Y Sung; John S Tam; Y M Dennis Lo
Journal:  Clin Chem       Date:  2003-12       Impact factor: 8.327

6.  A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).

Authors:  Ying-Hui Jin; Lin Cai; Zhen-Shun Cheng; Hong Cheng; Tong Deng; Yi-Pin Fan; Cheng Fang; Di Huang; Lu-Qi Huang; Qiao Huang; Yong Han; Bo Hu; Fen Hu; Bing-Hui Li; Yi-Rong Li; Ke Liang; Li-Kai Lin; Li-Sha Luo; Jing Ma; Lin-Lu Ma; Zhi-Yong Peng; Yun-Bao Pan; Zhen-Yu Pan; Xue-Qun Ren; Hui-Min Sun; Ying Wang; Yun-Yun Wang; Hong Weng; Chao-Jie Wei; Dong-Fang Wu; Jian Xia; Yong Xiong; Hai-Bo Xu; Xiao-Mei Yao; Yu-Feng Yuan; Tai-Sheng Ye; Xiao-Chun Zhang; Ying-Wen Zhang; Yin-Gao Zhang; Hua-Min Zhang; Yan Zhao; Ming-Juan Zhao; Hao Zi; Xian-Tao Zeng; Yong-Yan Wang; Xing-Huan Wang
Journal:  Mil Med Res       Date:  2020-02-06

7.  Possible central nervous system infection by SARS coronavirus.

Authors:  Kwok-Kwong Lau; Wai-Cho Yu; Chung-Ming Chu; Suet-Ting Lau; Bun Sheng; Kwok-Yuen Yuen
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

8.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia.

Authors:  Mustafa Saad; Ali S Omrani; Kamran Baig; Abdelkarim Bahloul; Fatehi Elzein; Mohammad Abdul Matin; Mohei A A Selim; Mohammed Al Mutairi; Daifullah Al Nakhli; Amal Y Al Aidaroos; Nisreen Al Sherbeeni; Hesham I Al-Khashan; Ziad A Memish; Ali M Albarrak
Journal:  Int J Infect Dis       Date:  2014-10-07       Impact factor: 3.623

9.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.

Authors:  Hongzhou Lu; Charles W Stratton; Yi-Wei Tang
Journal:  J Med Virol       Date:  2020-02-12       Impact factor: 2.327

10.  Seasonal distribution of febrile seizure and the relationship with respiratory and enteric viruses in Korean children based on nationwide registry data.

Authors:  Do Hoon Han; Su Yeong Kim; Na Mi Lee; Dae Yong Yi; Sin Weon Yun; In Seok Lim; Soo Ahn Chae
Journal:  Seizure       Date:  2019-10-18       Impact factor: 3.184

  10 in total
  10 in total

1.  Status epilepticus due to COVID-19; a cases series and literature review.

Authors:  Mohsen Kheradmand; Helia Hemasian; Fariborz Khorvash; Mohammad Reza Najafi; Keyvan Ghadimi; Khatereh Forouharnejad; Mohammad Amin Najafi
Journal:  Am J Neurodegener Dis       Date:  2022-06-20

Review 2.  Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children.

Authors:  Aleksandra S Dain; Leslie Raffini; Hilary Whitworth
Journal:  Curr Opin Pediatr       Date:  2022-06-01       Impact factor: 2.893

Review 3.  Diagnosis and Acute Management of COVID-19 and Multisystem Inflammatory Syndrome in Children.

Authors:  Teresa B Kortz; Emilia Connolly; C Lee Cohen; Rebecca E Cook; Jennifer A Jonas; Michael S Lipnick; Niranjan Kissoon
Journal:  Pediatr Emerg Care       Date:  2021-10-01       Impact factor: 1.602

Review 4.  Status epilepticus and COVID-19: A systematic review.

Authors:  Fedele Dono; Bruna Nucera; Jacopo Lanzone; Giacomo Evangelista; Fabrizio Rinaldi; Rino Speranza; Serena Troisi; Lorenzo Tinti; Mirella Russo; Martina Di Pietro; Marco Onofrj; Laura Bonanni; Giovanni Assenza; Catello Vollono; Francesca Anzellotti; Francesco Brigo
Journal:  Epilepsy Behav       Date:  2021-03-17       Impact factor: 3.337

5.  Severe cortical damage associated with COVID-19 case report.

Authors:  Luca Zombori; Melody Bacon; Hannah Wood; Fiona Chatterjee; Ramesh Venkateswaran; Simona Lampariello; Michael Yoong
Journal:  Seizure       Date:  2020-11-23       Impact factor: 3.184

Review 6.  Neurological Complications of COVID-19: Underlying Mechanisms and Management.

Authors:  Ghaydaa A Shehata; Kevin C Lord; Michaela C Grudzinski; Mohamed Elsayed; Ramy Abdelnaby; Hatem A Elshabrawy
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

7.  Evaluation of Febrile Seizure Diagnoses Associated With COVID-19.

Authors:  Katsiah Cadet; Jessica Boegner; Gary D Ceneviva; Neal J Thomas; Conrad Krawiec
Journal:  J Child Neurol       Date:  2022-03-14       Impact factor: 2.363

8.  New-Onset Non-convulsive Status Epilepticus in Previously Healthy COVID-19 Patient.

Authors:  Ika Noviawaty
Journal:  Cureus       Date:  2022-08-22

Review 9.  Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes.

Authors:  Mônica O Santos; Lucas C Gonçalves; Paulo A N Silva; André L E Moreira; Célia R M Ito; Fernanda A O Peixoto; Isabela J Wastowski; Lilian C Carneiro; Melissa A G Avelino
Journal:  J Pediatr (Rio J)       Date:  2021-12-03       Impact factor: 2.990

10.  Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature.

Authors:  L Siracusa; A Cascio; S Giordano; A A Medaglia; G A Restivo; I Pirrone; G F Saia; F Collura; C Colomba
Journal:  Ital J Pediatr       Date:  2021-06-02       Impact factor: 2.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.